Comparison of efficacy, side effects, and patient satisfaction in patients with limited scalp areata alopecia in a multiple group study with Latanoprost, Minoxidil, and Betamethasone

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211109053013N1

Enrollment

108

Registered

2021-12-03

Start date

2021-12-06

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

alopecia areata. Alopecia areata

Interventions

Intervention 1: Intervention group: Latanoprost 0.005% topical eye drops alone

Apply 50 microliters (1 drop) twice daily. Intervention 2: Intervention group: topical minoxidil solution 5% alone

1 cc twice daily. Intervention 3: Intervention group: topical eye drops Latanoprost 0.005% and topical solution minoxidil 5%

Latanoprost 50 µl (1 drop) in the morning and Minoxidil 1 cc in the afternoon. Intervention 4: Intervention group: Topical betamethasone solution 0.1 and topical minoxidil solution 5%: betamethasone 1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with localized areata alopecia of beard or scalp (<3 patches) Not receiving any medication for areata alopecia for at least 1 month before the beginning of the study Signing an informed written consent

Exclusion criteria

Exclusion criteria: Patients with extensive alopecia (> 3 patches) Patients with any systemic disorder , ophthalmic pathology, other dermatological diseases, skin atrophy, or infection at the alopecic region Patients with allergy or hypersensitivity to any component of the treatment products Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
The severity of alopecia was determined by the severity of alopecia tool (SALT) score before and after therapy. Scalp hair loss grading will be as below: S0=no hair loss; S1 < 25% hair loss; S2 =25–49%hair loss; S3=50–74% hair loss; S4=75–99% hair loss and S5=100% hair loss. Grades of body hair loss included: B0, nobody hair loss; B1, some body hair loss, and B2, 100% body(excluding scalp) hair loss. Timepoint: Calculation of SALT score at the beginning of the study (before the intervention) and 2 and 6 weeks after treatment begins. Method of measurement: Regrowth was calculated as [(SALT score at base line-SALTscore at follow-up)/SALT score at base line] 100 and was categorized as A0= no change or further loss, A1=1–24% regrowth, A2=25–49% regrowth, A3=50–74% regrowth, A4=75–99%regrowth and A5=100% regrowth.	—

Measure

Time frame

The severity of alopecia was determined by the severity of alopecia tool (SALT) score before and after therapy. Scalp hair loss grading will be as below: S0=no hair loss; S1 < 25% hair loss; S2 =25–49%hair loss; S3=50–74% hair loss; S4=75–99% hair loss and S5=100% hair loss. Grades of body hair loss included: B0, nobody hair loss; B1, some body hair loss, and B2, 100% body(excluding scalp) hair loss. Timepoint: Calculation of SALT score at the beginning of the study (before the intervention) and 2 and 6 weeks after treatment begins. Method of measurement: Regrowth was calculated as [(SALT score at base line-SALTscore at follow-up)/SALT score at base line] 100 and was categorized as A0= no change or further loss, A1=1–24% regrowth, A2=25–49% regrowth, A3=50–74% regrowth, A4=75–99%regrowth and A5=100% regrowth.

—

Secondary

Measure	Time frame
Patients' satisfaction of treatment. Timepoint: At the beginning of the study (before the intervention) and 2 and 6 weeks after treatment begins. Method of measurement: By using a questionnaire: (1= no response, 2=fair improvement,3=good improvement, 4=very good improvement and 5=excellent improvement).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNafise Yazdanian

Iran University of Medical Sciences

nf.yazdanian71@gmail.com+98 21 6643 6277

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026